"prostate carcinoma, cellular senescence, radioresistance, DNA damage response, cytokines, signalling pathways"@en . . "prostate carcinoma" . . . . . " cellular senescence" . . . "Mechanismy radiorezistence n\u00E1dorov\u00FDch bun\u011Bk prostaty" . "Prostate carcinoma (CaP) is the most frequent cancer in men of advanced age and fourth most frequent cause of death of oncologic origin in men worldwide. Despite the advances in diagnosis and therapy of CaP, the mortality remains almost the same for the last 40 years. Nowadays, the most successful therapeutic modality of localized CaP is radical prostatectomy combined with immediate postoperative radiotherapy significantly improving metastasis free survival and overall survival, where the median of 15-year survival is around 47%. However, the rest of patients develop metastatic form of CaP that is fully incurable due to resistance of prostate cancer cells to androgen ablation, radiotherapy and current chemotherapeutics. The main goal of this proposal is deciphering the molecular mechanisms of radioresistance of primary and metastatic CaP in relation to epithelial-mesenchymal transition, development of cellular senescence and cytokine expression. Our understanding of radioresistance of CaP is fundamental for future efforts to develop efficient therapeutic modalities of advanced CaP"@en . . "2014-03-31+02:00"^^ . . "http://www.isvav.cz/projectDetail.do?rowId=GA13-17658S"^^ . "GA13-17658S" . "1"^^ . "0"^^ . . "1"^^ . " radioresistance" . "1"^^ . . " cytokines" . "Karcinom prostaty (CaP) je nejroz\u0161\u00ED\u0159en\u011Bj\u0161\u00ED n\u00E1dorov\u00E9 onemocn\u011Bn\u00ED mu\u017E\u016F v pokro\u010Dil\u00E9m v\u011Bku a \u010Dtvrt\u00E1 nej\u010Dast\u011Bj\u0161\u00ED p\u0159\u00ED\u010Dina smrti onkologick\u00E9ho p\u016Fvodu u mu\u017E\u016F po cel\u00E9m sv\u011Bt\u011B. P\u0159es pokroky v diagnostice a terapii, mortalita pacient\u016F z\u016Fst\u00E1v\u00E1 v posledn\u00EDch 40 letech t\u00E9m\u011B\u0159 stejn\u00E1. V sou\u010Dasnosti nej\u00FA\u010Dinn\u011Bj\u0161\u00ED l\u00E9\u010Dbou lokalizovan\u00E9ho CaP je radik\u00E1ln\u00ED prostatektomie kombinovan\u00E1 bezprost\u0159edn\u011B s pooperativn\u00ED radioterapi\u00ED, kter\u00E1 v\u00FDznamn\u011B zlep\u0161uje obdob\u00ED bez metast\u00E1z a celkov\u00E9 p\u0159e\u017Eit\u00ED (medi\u00E1n 15 let\u00E9ho p\u0159e\u017Eit\u00ED je okolo 47%). Bohu\u017Eel, u zbytku pacient\u016F doch\u00E1z\u00ED k rozvoji metastatick\u00E9 formy CaP, kter\u00E1 je zcela nel\u00E9\u010Diteln\u00E1 vzhledem k rezistenci n\u00E1dorov\u00FDch bun\u011Bk v\u016F\u010Di antiandrogenn\u00ED terapii, radioterapii a sou\u010Dasn\u00FDm chemoterapeutik\u016Fm. Hlavn\u00EDm c\u00EDlem tohoto n\u00E1vrhu je objasn\u011Bn\u00ED molekul\u00E1rn\u00EDch mechanism\u016F radiorezistence u prim\u00E1rn\u00EDho a metastatick\u00E9ho CaP a to ve vztahu k epiteli\u00E1ln\u00ED-mesenchym\u00E1ln\u00ED transici, rozvoji bun\u011B\u010Dn\u00E9 senescence a expresi cytokin\u016F. Porozum\u011Bn\u00ED radiorezistenci CaP je z\u00E1sadn\u00ED pro na\u0161e dal\u0161\u00ED \u00FAsil\u00ED vyvinout u\u010Dinn\u011Bj\u0161\u00ED zp\u016Fsoby terapie pokro\u010Dil\u00E9ho CaP." . "0"^^ . . . . . "2015-04-23+02:00"^^ . "2016-12-31+01:00"^^ . . "2013-02-01+01:00"^^ . . . "Mechanisms of radioresistance of prostate cancer cells"@en . " DNA damage response" .